top_banner
Cancer News

Recent Breast Cancer News
Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer (May 6, 2019)

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered... Continue Reading

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer (April 30, 2019)

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of... Continue Reading

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer (April 8, 2019)

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The... Continue Reading

Immunotherapy Offers New Hope in Triple Negative Breast Cancer (December 28, 2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed... Continue Reading

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (December 21, 2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology... Continue Reading

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer (December 19, 2018)

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death... Continue Reading

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (December 12, 2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual... Continue Reading

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (December 11, 2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented... Continue Reading

Choice of surgery may affect quality of life for young breast cancer survivors (December 10, 2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research... Continue Reading

20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer (October 31, 2018)

Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT) may be beneficial for patients with breast cancer and more than 9 involved axially lymph nodes (ALN), according to... Continue Reading

Next Page »